Navin Fluorine Reports Strong Q2 & H1 FY26 Results, Announces Major Capex for Growth
Navin Fluorine reported strong Q2 & H1 FY26 financial results with significant Y-o-Y growth in sales and profit. The company announced major capex for HFC and MPP capacity expansion, targeting future revenue potential.
The announcement includes impressive financial performance, substantial capital expenditure plans with significant revenue potential, and a positive outlook for future business, which collectively suggest a high impact on the company's valuation and market position.
The company demonstrated robust financial growth across all key metrics for Q2 and H1 FY26. Strategic capex announcements and positive outlooks for business segments indicate strong future growth prospects and operational efficiency.
Navin Fluorine International Limited has released its Investor Presentation for the quarter and half year ended September 30, 2025 (Q2 & H1 of FY 2025-26), highlighting robust financial performance and strategic expansion plans: Consolidated Financial Performance (Q2 FY26 vs Q2 FY25): * Sales increased by 46% year-on-year (Y-o-Y) to ₹758.4 crore. * Operating EBITDA grew by 129% Y-o-Y to ₹246.2 crore, with Operating EBITDA Margin at 32.5% (+1176 bps Y-o-Y). * Operating PBT surged by 173% Y-o-Y to ₹179.3 crore. * Profit After Tax (PAT) increased by 152.24% Y-o-Y to ₹148.37 crore. Consolidated Financial Performance (H1 FY26 vs H1 FY25): * Sales rose by 42% Y-o-Y to ₹1483.8 crore. * Operating EBITDA increased by 118% Y-o-Y to ₹453.0 crore, with Operating EBITDA Margin at 30.5% (+1060 bps Y-o-Y). * Operating PBT grew by 159% Y-o-Y to ₹320.5 crore. * PAT increased by 141.36% Y-o-Y to ₹265.54 crore. Key Business Highlights (Q2 FY26): * HPP: Revenue growth of 38% Y-o-Y due to higher realizations and volumes. AHF capex mechanical trials are underway, with commissioning targeted by Q3 FY26. * Specialty Chemicals: Revenue growth of 39% Y-o-Y, with a strong outlook for H2. The Chemours project is on track for completion in Q1 FY27. * CDMO: Achieved 98% Y-o-Y revenue growth, supported by a robust order book pipeline till FY27. Validation batches for a European CDMO MSA have started, with supplies targeted by January 2026. Capex Announcements: * Additional HFC capacity: An investment of ₹236.5 crore (funded by internal accruals) for up to 15,000 MTPA of R32, expected to be commissioned by Q3 FY27, with a peak revenue potential of ~₹600-825 crore per annum. * De-bottlenecking MPP capacity at Dahej: A capex of ₹75 crore (funded by internal accruals) to support a new molecule for a global innovator, targeted for commissioning by Q3 FY27, with a peak revenue potential of ~₹140-160 crore per annum. ESG & R&D: * Significant environmental initiatives were undertaken in FY25 across plants, including waste heat recovery, steam condensate recovery, and increased solar electricity capacity at Dewas from 1 MW to 2.2 MW in September 2024. * Total R&D spend in FY25 was ₹54.69 crore, focusing on developing fluorinated specialty chemicals and contract development. Dividends: The company maintains a track record of progressive dividends, with FY25 dividends including a Special 140%, Final 150%, and Interim 75%.
What to do with a filing like this
Navin Fluorine International Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Navin Fluorine International Limited. Read the original for the full detail.